Daily Respiratory Research Analysis
Three impactful advances span surveillance, immunotherapy, and mechanism. A modeling study shows that small, well-placed aircraft wastewater sentinel networks can provide early warning for respiratory pandemics. A phase 1/2 DNA immunotherapy (INO-3107) reduced surgical burden and elicited robust HPV-specific T-cell responses in recurrent respiratory papillomatosis, while a Cell study identifies lung-derived pro‑thrombotic extracellular vesicles driving cancer-associated thrombosis and metastasis
Summary
Three impactful advances span surveillance, immunotherapy, and mechanism. A modeling study shows that small, well-placed aircraft wastewater sentinel networks can provide early warning for respiratory pandemics. A phase 1/2 DNA immunotherapy (INO-3107) reduced surgical burden and elicited robust HPV-specific T-cell responses in recurrent respiratory papillomatosis, while a Cell study identifies lung-derived pro‑thrombotic extracellular vesicles driving cancer-associated thrombosis and metastasis via integrin β2.
Research Themes
- Aircraft wastewater genomic surveillance for respiratory pandemics
- DNA immunotherapy for airway papillomatosis
- Extracellular vesicles, thrombosis and lung microenvironment
Selected Articles
1. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2.
This study identifies a lung 'pro-thrombotic niche' where CXCL13-reprogrammed interstitial macrophages secrete small EVs carrying clustered integrin β2, which promote thrombosis and metastasis. It mechanistically links lung microenvironment-derived EVs to systemic thromboinflammation in cancer, highlighting ITGB2 and CXCL13 axes as therapeutic targets.
Impact: Reveals a previously unrecognized lung-derived EV mechanism that connects thrombosis to metastasis and provides tractable targets (integrin β2, CXCL13) for intervention. High translational relevance across cancers with thrombotic complications.
Clinical Implications: Suggests potential for anti-integrin β2 or CXCL13 pathway modulation to reduce cancer-associated thrombosis and possibly metastasis. May inform biomarker development using EV cargo for thrombotic risk stratification.
Key Findings
- Defined a lung 'pro-thrombotic niche' consisting of CXCL13-reprogrammed interstitial macrophages secreting pro-thrombotic sEVs.
- sEVs carried clustered integrin β2, mechanistically linking EV cargo to platelet/immune activation, thrombosis, and metastasis.
- Findings generalize across multiple cancers with non-metastatic lung microenvironments, indicating a systemic role of lung-derived EVs.
Methodological Strengths
- Multi-system mechanistic approach integrating EV biology and tumor–host microenvironment interactions
- Use of molecular characterization of EV cargo (integrin β2 clustering) to link phenotype to function
Limitations
- Predominantly preclinical mechanistic evidence; interventional validation in humans is needed
- Details of human cohort validation and causal therapeutics are not established in this report
Future Directions: Develop anti-ITGB2 or anti-CXCL13 strategies; validate EV-based biomarkers of thrombotic risk; test whether modulating the lung PTN reduces thrombosis/metastasis clinically.
Cancer is a systemic disease with complications beyond the primary tumor site. Among them, thrombosis is the second leading cause of death in patients with certain cancers (e.g., pancreatic ductal adenocarcinoma [PDAC]) and advanced-stage disease. Here, we demonstrate that pro-thrombotic small extracellular vesicles (sEVs) are secreted by C-X-C motif chemokine 13 (CXCL13)-reprogrammed interstitial macrophages in the non-metastatic lung microenvironment of multiple cancers, a niche that we define as the pro-thrombotic niche (PTN). These sEVs package clustered integrin β
2. Pandemic monitoring with global aircraft-based wastewater surveillance networks.
Modeling shows that 10–20 strategically placed airport wastewater sentinel sites can serve as an effective early warning system for respiratory pandemics, with diminishing returns beyond a critical number. The framework identifies blind spots and optimization strategies, and retrospective analyses indicate markedly shortened detection times.
Impact: Offers a scalable, resource-efficient public health surveillance strategy for respiratory threats with actionable design principles. Particularly timely for post-COVID preparedness.
Clinical Implications: Public health systems can deploy small, optimized airport WWSNs to gain early signals of variant introduction and spread, informing clinical testing, hospital preparedness, and targeted interventions.
Key Findings
- Networks with 10–20 sentinel airports provided timely situational awareness and effective early warning for respiratory pathogens.
- Beyond a critical number of sites, additional sentinels yielded diminishing returns, emphasizing resource optimization.
- Retrospective analyses showed aircraft wastewater networks can shorten detection time for emerging pathogens.
Methodological Strengths
- Actionable computational framework with optimization and blind-spot analysis
- Retrospective validation demonstrating shortened detection timelines
Limitations
- Model-based inferences depend on assumptions about travel patterns and shedding dynamics
- Real-world prospective implementation and cost-effectiveness analyses remain to be demonstrated
Future Directions: Prospective pilot deployments at selected airports, integration with clinical and syndromic surveillance, and evaluation of cost-effectiveness and equity.
Aircraft wastewater surveillance has been proposed as a new approach to monitor the global spread of pathogens. Here we develop a computational framework providing actionable information for the design and estimation of the effectiveness of global aircraft-based wastewater surveillance networks (WWSNs). We study respiratory diseases of varying transmission potential and find that networks of 10-20 strategically placed wastewater sentinel sites can provide timely situational awareness and function effectively as an early warning system. The model identifies potential blind spots and suggests optimization strategies to increase WWSN effectiveness while minimizing resource use. Our findings indicate that increasing the number of sentinel sites beyond a critical threshold does not proportionately improve WWSN capabilities, emphasizing the importance of resource optimization. We show, through retrospective analyses, that WWSNs can notably shorten detection time for emerging pathogens. The approach presented offers a realistic analytic framework for the analysis of WWSNs at airports.
3. DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.
In a 52-week, single-arm phase 1/2 study (n=32), INO-3107 reduced surgical interventions in 81% of adults with HPV-6/11 RRP and elicited robust HPV-specific T-cell responses that trafficked to papillomas. Safety was favorable with only low-grade treatment-related adverse events.
Impact: Provides first-in-class clinical evidence that DNA immunotherapy can reduce surgical burden in RRP while demonstrating mechanistic T-cell trafficking. Opens a new therapeutic avenue for a burdensome airway disease.
Clinical Implications: INO-3107 may shift RRP management from repeated surgeries toward immunotherapy, pending randomized trials. Immunomonitoring (HPV-specific T cells) could guide response assessment.
Key Findings
- 81% (26/32) of patients had reduced surgical interventions over 52 weeks after INO-3107.
- HPV-6/11 antigen-specific T cells were induced; TCR sequencing showed emergent clones trafficking to papillomas.
- Safety profile showed only low-grade treatment-related adverse events (41%).
Methodological Strengths
- Prospective 52-week follow-up with integrated immunogenicity, transcriptomics and TCR clonotyping
- Clinically meaningful endpoint (reduction in surgeries) aligned with patient burden
Limitations
- Single-arm, open-label phase 1/2 design without randomized control
- Small sample size limits generalizability; durability beyond one year remains unknown
Future Directions: Conduct randomized controlled trials against standard care, define predictors of response via immunoprofiling, and assess long-term durability and dosing optimization.
Recurrent respiratory papillomatosis (RRP) is a chronic airway disease caused by Human Papillomavirus (HPV). INO-3107, DNA immunotherapy designed to elicit T-cells against HPV-6 and HPV-11, was evaluated in a 52-week Phase 1/2 study for efficacy, safety, and immunogenicity (NCT04398433). Thirty-two eligible adults with HPV-6 and/or HPV-11 RRP, requiring ≥2 surgical interventions in the year preceding dosing were enrolled between October 2020 and November 2021 and administered 4 INO-3107 doses by intramuscular injection followed by electroporation. The primary endpoint was safety and tolerability, as assessed by treatment-emergent adverse events (TEAEs). Secondary endpoints included surgical intervention frequency and change in RRP Severity Score (modified) post-INO-3107 and assessment of immune responses. 81% (26/32) of patients experienced surgery reduction following INO-3107 compared with the year prior to treatment. Blood assessments revealed HPV-6 and HPV-11 antigen-specific T-cell induction. RNA sequencing identified an inflammatory response in papillomas, inclusive of cytolytic CD8 + T-cell signatures. T-cell receptor sequencing revealed emergent T-cell clones in blood and confirmed trafficking to papillomas. Treatment-related adverse events (AEs) were reported in 13/32 (41%) patients, all low-grade. INO-3107 provides clinical benefit to HPV-6 and/or HPV-11-associated RRP adults and is well-tolerated. Importantly, treatment-induced peripheral T-cell responses traffic to airway tissue and are associated with clinical response.